Sandoz To Pay $195M Penalty For 4 Antitrust Violations In Generic Drug Trade

(March 3, 2020, 2:27 PM EST) -- PHILADELPHIA — Generic drug manufacturer Sandoz Inc. on March 2 agreed to a three-year deferred prosecution agreement for four antitrust violations in a Pennsylvania federal court and agreed to pay a $195 million penalty (United States v. Sandoz Inc., No. 20-cr-111, E.D. Pa.)....